ChronoScale appoints Andrew Schaap to board, grants 200,000 restricted shares

EKSO BIONICS HOLDINGS, INC.

Board expanded from 7 to 8 members; Schaap appointed effective June 29, 2026.
Schaap joins Audit Committee (replacing Douglas Miller) and Related Party Transactions Committee.
Schaap receives 200,000 restricted shares vesting 50% on each of first two anniversaries.
Subsidiary has a data center lease with a company where Schaap is CEO; lease was in ordinary course.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Andrew Cordell Schaap

Director

CHRN · EKSO BIONICS HOLDINGS, INC.

Effective: 2026-06-29
Filed: June 30, 2026, 4:43 PM ET

On June 29, 2026, the board of directors (the “Board”) of ChronoScale Corporation, a Nevada corporation (the “Company”), increased the size of the Board from seven to eight members and appointed Mr. Andrew Cordell Schaap to serve as a member of the Board to fill the resulting vacancy, effective as of June 29, 2026.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Andrew Cordell Schaap was appointed as Director at EKSO BIONICS HOLDINGS, INC..

Action: appointed
Role: Director

Exact text from the filing

On June 29, 2026, the board of directors (the “Board”) of ChronoScale Corporation, a Nevada corporation (the “Company”), increased the size of the Board from seven to eight members and appointed Mr. Andrew Cordell Schaap to serve as a member of the Board to fill the resulting vacancy, effective as of June 29, 2026.

View on SEC.gov

EKSO BIONICS HOLDINGS, INC. filing history →

Source: SEC EDGAR

accession 0001493152-26-031298

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.